Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Dr. Hedner has been active in the field of Thrombosis and Haemostasis for more than 40 years and initiated the idea to use FVIIa as a hemostatic drug when working as a clinician at the University Hospital of Malmö, Lund University, Sweden, in the 1970s. Later, she led the development of recombinant FVIIa when being part of the Department of Research & Development at the Danish pharmaceutical company Novo Nordisk A/S, Bagsværd, Denmark.
Dr. Hedner was a physician at the Department of Bleeding Disorders including a Haemophilia Comprehensive Clinic, Malmö University Hospital, University of Lund, Sweden from 1972-1983 . Her research and teaching experience was at the Medical Faculty of Lund University, Sweden and Professor in Clinical Coagulation Research at the University of Gothenburg and at the University of Lund.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur 9fa79bd953a34ce5f345e3c85c7e09fa
Quantité disponible : Plus de 20 disponibles
Vendeur : Basi6 International, Irving, TX, Etats-Unis
Etat : Brand New. New. US edition. Print on demand title. Delivery takes 20-25 days. Excellent Customer Service. N° de réf. du vendeur POD-17416
Quantité disponible : Plus de 20 disponibles
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 199 pages. 8.75x6.00x0.50 inches. In Stock. N° de réf. du vendeur __0128124393
Quantité disponible : 2 disponible(s)
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences. 214 pp. Englisch. N° de réf. du vendeur 9780128124390
Quantité disponible : 2 disponible(s)
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Paperback / softback. Etat : New. New copy - Usually dispatched within 4 working days. N° de réf. du vendeur B9780128124390
Quantité disponible : Plus de 20 disponibles
Vendeur : online-buch-de, Dozwil, Suisse
Paperback Jul 06, 2017. Etat : gebraucht; wie neu. N° de réf. du vendeur 563-3-10
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences. N° de réf. du vendeur 9780128124390
Quantité disponible : 2 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Treating Life-Threatening Bleedings | Development of Recombinant Coagulation Factor Viia | Ulla Hedner | Taschenbuch | Englisch | 2017 | Elsevier Science | EAN 9780128124390 | Verantwortliche Person für die EU: Zeitfracht Medien GmbH, Ferdinand-Jühlke-Str. 7, 99095 Erfurt, produktsicherheit[at]zeitfracht[dot]de | Anbieter: preigu. N° de réf. du vendeur 126702372
Quantité disponible : 5 disponible(s)